for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover
The Lancet
Journal Prestige (SJR): 14.934
Citation Impact (citeScore): 9
Number of Followers: 2569  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 0140-6736 - ISSN (Online) 1474-547X
Published by Elsevier Homepage  [3157 journals]
  • A dark day for universal health coverage
    • Abstract: Publication date: Available online 17 January 2019Source: The LancetAuthor(s): Julio Frenk, Octavio Gómez-Dantés, Felicia Marie Knaul
       
  • The 21st-century great food transformation
    • Abstract: Publication date: Available online 16 January 2019Source: The LancetAuthor(s): Tamara Lucas, Richard Horton
       
  • Food in the Anthropocene: the EAT–Lancet Commission on healthy diets
           from sustainable food systems
    • Abstract: Publication date: Available online 16 January 2019Source: The LancetAuthor(s): Walter Willett, Johan Rockström, Brent Loken, Marco Springmann, Tim Lang, Sonja Vermeulen, Tara Garnett, David Tilman, Fabrice DeClerck, Amanda Wood, Malin Jonell, Michael Clark, Line J Gordon, Jessica Fanzo, Corinna Hawkes, Rami Zurayk, Juan A Rivera, Wim De Vries, Lindiwe Majele Sibanda, Ashkan Afshin
       
  • Department of Error
    • Abstract: Publication date: Available online 15 January 2019Source: The LancetAuthor(s):
       
  • Medically assisted reproduction and birth outcomes: a within-family
           analysis using Finnish population registers
    • Abstract: Publication date: Available online 14 January 2019Source: The LancetAuthor(s): Alice Goisis, Hanna Remes, Pekka Martikainen, Reija Klemetti, Mikko MyrskyläSummaryBackgroundChildren born after medically assisted reproduction are at higher risk of adverse birth outcomes than are children conceived naturally. We aimed to establish the extent to which this excess risk should be attributed to harmful effects of treatment or to pre-existing parental characteristics that confound the association.MethodsWe used data from Finnish administrative registers covering a 20% random sample of households with at least one child aged 0–14 years at the end of 2000 (n=65 723). We analysed birthweight, gestational age, risk of low birthweight, and risk of preterm birth among children conceived both by medically assisted reproduction and naturally. First, we estimated differences in birth outcomes by mode of conception in the general population, using standard multivariate methods that controlled for observed factors (eg, multiple birth, birth order, and parental sociodemographic characteristics). Second, we used a sibling-comparison approach that has not been used before in medically assisted reproduction research. We compared children conceived by medically assisted reproduction with siblings conceived naturally and, thus, controlled for all observed and unobserved factors shared by siblings.FindingsBetween 1995 and 2000, 2776 (4%) children in our sample were conceived by medically assisted reproduction; 1245 children were included in the sibling comparison. Children conceived by medically assisted reproduction had worse outcomes than did those conceived naturally, for all outcomes, even after adjustments for observed child and parental characteristics—eg, difference in birthweight of −60 g (95% CI −86 to −34) and 2·15 percentage point (95% CI 1·07 to 3·24) increased risk of preterm delivery. In the sibling comparison, the gap in birth outcomes was attenuated, such that the relation between medically assisted reproduction and adverse birth outcomes was statistically and substantively weak for all outcomes—eg, difference in birthweight of −31 g (95% CI −85 to 22) and 1·56 percentage point (95% CI −1·26 to 4·38) increased risk of preterm delivery.InterpretationChildren conceived by medically assisted reproduction face an elevated risk of adverse birth outcomes. However, our results indicate that this increased risk is largely attributable to factors other than the medically assisted reproduction treatment itself.FundingEuropean Research Council, the Academy of Finland, and the Signe and Ane Gyllenberg Foundation.
       
  • Assessing in-vitro fertilisation at age 40 years
    • Abstract: Publication date: Available online 14 January 2019Source: The LancetAuthor(s): Norbert Gleicher, David H Barad
       
  • Logistical challenges in the DR Congo Ebola virus response
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Miriam Shuchman
       
  • Department of Error
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s):
       
  • Department of Error
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s):
       
  • Laennec's cirrhosis
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Alain Braillon
       
  • Snakebite envenoming
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Himmatrao Saluba Bawaskar, Pramodini Himmatrao Bawaskar
       
  • Snakebite envenoming
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Christian John Hunter, Karl-Heinz Piechazek, Peter Mokua Nyarang'o, Timothy Rennie
       
  • Multimorbidity and patient-centred care in the 3D trial – Authors'
           reply
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Chris Salisbury, Peter Bower, Bruce Guthrie, Stewart Mercer
       
  • Multimorbidity and patient-centred care in the 3D trial
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Zhijie Xu, Mi Yao, Lizheng Fang
       
  • Multimorbidity and patient-centred care in the 3D trial
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Alessandra Marengoni, Davide L Vetrano, Amaia Calderón-Larrañaga, Graziano Onder
       
  • Multimorbidity and patient-centred care in the 3D trial
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Elizabeth Ann Sturgiss, Pauline Boeckxstaens, Alexander M Clark
       
  • Multimorbidity and patient-centred care in the 3D trial
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Nick Lewis-Barned, Angela Coulter, Simon Eaton, Sue Roberts
       
  • Picturing health: living with bipolar disorder
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Matthieu Zellweger
       
  • Hyperphosphataemic tumoral calcinosis
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Vivek Tiwari, Alpesh Goyal, Manoj Nagar, John A Santoshi
       
  • Canada to widen its newly opened retail cannabis market
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Paul Webster
       
  • Head of Italian research institute resigns over “anti-scientific
           position” of government
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Talha Burki
       
  • Offline: Rosa Luxemburg and the struggle for health
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Richard Horton
       
  • Health-emergency disaster risk management and research ethics
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Emily Y Y Chan, Katharine Wright, Michael Parker
       
  • Cervical cancer: unequal progress
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): The Lancet
       
  • Was DR Congo's Ebola virus outbreak used as a political tool'
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): The Lancet
       
  • 2019 in the USA: shutdowns and showdowns
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): The Lancet
       
  • Cervical cancer
    • Abstract: Publication date: 12–18 January 2019Source: The Lancet, Volume 393, Issue 10167Author(s): Paul A Cohen, Anjua Jhingran, Ana Oaknin, Lynette DennySummaryEach year, more than half a million women are diagnosed with cervical cancer and the disease results in over 300 000 deaths worldwide. High-risk subtypes of the human papilloma virus (HPV) are the cause of the disease in most cases. The disease is largely preventable. Approximately 90% of cervical cancers occur in low-income and middle-income countries that lack organised screening and HPV vaccination programmes. In high-income countries, cervical cancer incidence and mortality have more than halved over the past 30 years since the introduction of formal screening programmes. Treatment depends on disease extent at diagnosis and locally available resources, and might involve radical hysterectomy or chemoradiation, or a combination of both. Conservative, fertility-preserving surgical procedures have become standard of care for women with low-risk, early-stage disease. Advances in radiotherapy technology, such as intensity-modulated radiotherapy, have resulted in less treatment-related toxicity for women with locally-advanced disease. For women with metastatic or recurrent disease, the overall prognosis remains poor; nevertheless, the incorporation of the anti-VEGF agent bevacizumab has been able to extend overall survival beyond 12 months. Preliminary results of novel immunotherapeutic approaches, similarly to other solid tumours, have shown promising results so far.
       
  • Carbohydrate and human health: is it all about quality'
    • Abstract: Publication date: Available online 10 January 2019Source: The LancetAuthor(s): Edward S Chambers, Claire S Byrne, Gary Frost
       
  • Does bovine lactoferrin prevent late-onset neonatal sepsis'
    • Abstract: Publication date: Available online 8 January 2019Source: The LancetAuthor(s): Lex W Doyle, Jeanie L Y Cheong
       
  • Born to run'
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Stephen Ginn
       
  • SGLT2 inhibitors for primary and secondary prevention of cardiovascular
           and renal outcomes in type 2 diabetes: a systematic review and
           meta-analysis of cardiovascular outcome trials
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S SabatineSummaryBackgroundThe magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on specific cardiovascular and renal outcomes and whether heterogeneity is based on key baseline characteristics remains undefined.MethodsWe did a systematic review and meta-analysis of randomised, placebo-controlled, cardiovascular outcome trials of SGLT2i in patients with type 2 diabetes. We searched PubMed and Embase for trials published up to Sept 24, 2018. Data search and extraction were completed with a standardised data form and any discrepancies were resolved by consensus. Efficacy outcomes included major adverse cardiovascular events (myocardial infarction, stroke, or cardiovascular death), the composite of cardiovascular death or hospitalisation for heart failure, and progression of renal disease. Hazard ratios (HRs) with 95% CIs were pooled across trials, and efficacy outcomes were stratified by baseline presence of atherosclerotic cardiovascular disease, heart failure, and degree of renal function.FindingsWe included data from three identified trials and 34 322 patients (60·2% with established atherosclerotic cardiovascular disease), with 3342 major adverse cardiovascular events, 2028 cardiovascular deaths or hospitalisation sfor heart failure events, and 766 renal composite outcomes. SGLT2i reduced major adverse cardiovascular events by 11% (HR 0·89 [95% CI 0·83–0·96], p=0·0014), with benefit only seen in patients with atherosclerotic cardiovascular disease (0·86 [0·80–0·93]) and not in those without (1·00 [0·87–1·16], p for interaction=0·0501). SGLT2i reduced the risk of cardiovascular death or hospitalisation for heart failure by 23% (0·77 [0·71–0·84], p
       
  • Department of Error
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s):
       
  • Department of Error
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s):
       
  • Department of Error
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s):
       
  • Department of Error
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s):
       
  • Unsuccessful trials of therapies for Alzheimer's disease – Authors'
           reply
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Roy M Anderson, Christoforos Hadjichrysanthou, Stephanie Evans, Kevin McRae-McKee, Mei Mei Wong
       
  • Unsuccessful trials of therapies for Alzheimer's disease
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Jonathan M Schott, Paul S Aisen, Jeffery L Cummings, Robert J Howard, Nick C Fox
       
  • Screening for abdominal aortic aneurysm – Authors' reply
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Minna Johansson, Per Henrik Zahl, Volkert Siersma, Karsten Juhl Jørgensen, Bertil Marklund, John Brodersen
       
  • Screening for abdominal aortic aneurysm
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Anders Wanhainen, Sverker Svensjö, Jan Holst, Martin Björck, Anders Gottsäter, Swedish Aneurysm Screening Study group and the Swedish Society for Vascular Surgery
       
  • Open letter from Chinese HIV professionals on human genome editing
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Linqi Zhang, Ping Zhong, Xiaomei Zhai, Yiming Shao, Shan Lu, 149 signatories
       
  • Gene-edited babies: Chinese Academy of Medical Sciences’ response
           and action
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Chen Wang, Xiaomei Zhai, Xinqing Zhang, Limin Li, Jianwei Wang, De-pei Liu, Chinese Academy of Medical Sciences
       
  • Chinese Academy of Engineering calls for actions on the birth of
           gene-edited infants
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Boli Zhang, Zuoning Chen, Jian Yi, Haiying Tang, Chen Wang, Chinese Academy of Engineering
       
  • Amit Sengupta
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Andrew Green
       
  • The evil eye
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Marco De Ambrogi
       
  • Reframing surgical simulation: the textile body as metaphor
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Roger Kneebone, Fleur Oakes, Colin Bicknell
       
  • Rina Agustina: tracking nutrition and child health
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): John Zarocostas
       
  • Dorothy Stopford Price and the control of tuberculosis in Ireland
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Georgina Ferry
       
  • Your digital nutritionist
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Dina Hamideh, Bianca Arellano, Eric J Topol, Steven R Steinhubl
       
  • Sub-Saharan Africa leads the way in medical drones
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Becky McCall
       
  • Research Focus: beyond the 100 000 genomes
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Geoff Watts
       
  • Offline: WHO powers up in 2019
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Richard Horton
       
  • Thailand's commitment to global cooperation on NCDs: acting together now
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Prayut Chan-o-cha
       
  • A new Health Index for England: the Chief Medical Officer's 2018 annual
           report
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Jonathan Pearson-Stuttard, Orla Murphy, Sally C Davies
       
  • Stopping medication for heart failure with improved ejection fraction
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Jane Wilcox, Clyde W Yancy
       
  • De-intensified treatment in human papillomavirus-positive oropharyngeal
           cancer
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Johannes Christiaan Oosthuizen, Jaime Doody
       
  • Pump, pipes, and filter: do SGLT2 inhibitors cover it all'
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Subodh Verma, Peter Jüni, C David Mazer
       
  • Looking ahead to 2019 in The Lancet
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): The Lancet
       
  • Successes and challenges for health in Indonesia
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): The Lancet
       
  • Ensuring and measuring universality in UHC
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): The Lancet
       
  • A 5-year-old boy with a chronic cough caused by Echinococcus
           granulosus
    • Abstract: Publication date: 5–11 January 2019Source: The Lancet, Volume 393, Issue 10166Author(s): Nasenien Nourkami-Tutdibi, Arne Simon, Peter Fries, Sören L Becker, Petra Ecker, Michael Zemlin, Sascha Meyer
       
  • PD-1 antibodies in head-and-neck cancer
    • Abstract: Publication date: Available online 30 November 2018Source: The LancetAuthor(s): Barbara Wollenberg
       
  • Department of Error
    • Abstract: Publication date: Available online 28 November 2018Source: The LancetAuthor(s):
       
  • Department of Error
    • Abstract: Publication date: Available online 9 November 2018Source: The LancetAuthor(s):
       
  • A two-drug regimen for antiretroviral therapy
    • Abstract: Publication date: Available online 9 November 2018Source: The LancetAuthor(s): Arne Kroidl, Joseph Eberle
       
  • Framing an agenda for children thriving in the SDG era: a
           WHO–UNICEF–Lancet Commission on Child Health and Wellbeing
    • Abstract: Publication date: Available online 2 November 2018Source: The LancetAuthor(s): Awa Coll-Seck, Helen Clark, Rajiv Bahl, Stefan Peterson, Anthony Costello, Tamara Lucas
       
  • Reducing the global burden of depression: a Lancet–World Psychiatric
           Association Commission
    • Abstract: Publication date: Available online 25 October 2018Source: The LancetAuthor(s): Helen Herrman, Christian Kieling, Patrick McGorry, Richard Horton, Jennifer Sargent, Vikram Patel
       
  • Informing NCD control efforts in India on the eve of Ayushman Bharat
    • Abstract: Publication date: Available online 12 September 2018Source: The LancetAuthor(s): Balram Bhargava, Vinod K Paul
       
  • Viroj Tangcharoensathien: master carpenter of Thai health care
    • Abstract: Publication date: Available online 1 February 2018Source: The LancetAuthor(s): Geoff Watts
       
  • Zhang's guideline to assess labour progression
    • Abstract: Publication date: Available online 20 December 2018Source: The LancetAuthor(s): Susanne Grylka-Baeschlin, Declan Devane
       
  • Antibiotic allergy
    • Abstract: Publication date: Available online 14 December 2018Source: The LancetAuthor(s): Kimberly G Blumenthal, Jonny G Peter, Jason A Trubiano, Elizabeth J PhillipsSummaryAntibiotics are the commonest cause of life-threatening immune-mediated drug reactions that are considered off-target, including anaphylaxis, and organ-specific and severe cutaneous adverse reactions. However, many antibiotic reactions documented as allergies were unknown or not remembered by the patient, cutaneous reactions unrelated to drug hypersensitivity, drug-infection interactions, or drug intolerances. Although such reactions pose negligible risk to patients, they currently represent a global threat to public health. Antibiotic allergy labels result in displacement of first-line therapies for antibiotic prophylaxis and treatment. A penicillin allergy label, in particular, is associated with increased use of broad-spectrum and non-β-lactam antibiotics, which results in increased adverse events and antibiotic resistance. Most patients labelled as allergic to penicillins are not allergic when appropriately stratified for risk, tested, and re-challenged. Given the public health importance of penicillin allergy, this Review provides a global update on antibiotic allergy epidemiology, classification, mechanisms, and management.
       
  • Toward improved evaluations of laws against drink-driving
    • Abstract: Publication date: Available online 12 December 2018Source: The LancetAuthor(s): Etienne Blais, Pierre Maurice
       
  • Confronting the most challenging risk factor: non-adherence
    • Abstract: Publication date: Available online 3 December 2018Source: The LancetAuthor(s): Richard Kones, Umme Rumana, Alberto Morales-Salinas
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 34.203.245.76
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-